---
title: "BRIEF: Metis TechBio launches $250 million Hong Kong IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285165668.md"
description: "Nanomaterials analysis company Metis TechBio Co. Ltd. launched its Hong Kong IPO on Tuesday, planning to raise approximately HKD 2 billion (USD 255 million) by selling 201 million shares at HKD 10.50 each. The subscription deadline is May 8, and trading is expected to begin on May 13. Based on the IPO price, the company's market capitalization is approximately HKD 12 billion. Eighteen cornerstone investors, including Blackstone, UBS, Mirae Asset Securities, and Orix Asia, have agreed to purchase 110 million shares, accounting for about 55% of the total shares sold. The company plans to use half of the IPO proceeds for research and development, 20% for ongoing and future clinical trials, and 10% for developing its animal health and longevity business"
datetime: "2026-05-05T07:11:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285165668.md)
  - [en](https://longbridge.com/en/news/285165668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285165668.md)
---

# BRIEF: Metis TechBio launches $250 million Hong Kong IPO

Nanomaterial analytics company **Metis TechBio Co. Ltd.** (7666.HK) on Tuesday **launched** its Hong Kong IPO, aiming to raise about HK$2 billion ($255 million) by selling 201 million shares for HK$10.50 each. The deadline for subscriptions is May 8, with trading of the stock set to begin on May 13.

At the IPO price, the company will have a market cap of about HK$12 billion. Eighteen cornerstone investors, including BlackRock, UBS, Mirae Asset Securities and Orix Asia, have agreed to purchase 110 million shares, or about 55% of the total being sold.

The company plans to use half of the IPO proceeds for R&D, 20% for ongoing and future clinical trials, and 10% to develop its animal health and longevity businesses. Metis TechBio reported 105 million yuan ($15.4 million) in revenue last year, up sharply from 1.5 million yuan in 2024. Its loss over that time narrowed to 392 million yuan last year from 499 million yuan in 2024.

_By Doug Young_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

## Related News & Research

- [Analysis-SpaceX IPO gives Musk sweeping power and curbs shareholder rights](https://longbridge.com/en/news/285354070.md)
- [BRIEF-Neuro Spectrum Insights Sees IPO Of 3.8 Mln Common Shares](https://longbridge.com/en/news/285245615.md)
- [The SpaceX IPO isn't here yet -- but this 2026 IPO is, and it looks like a steal](https://longbridge.com/en/news/285800094.md)
- [ANALYSIS-SpaceX IPO gives Musk sweeping power and curbs shareholder rights](https://longbridge.com/en/news/285350952.md)
- [The SpaceX IPO Is Coming: History Says the Stock Will Do This When It Starts Trading](https://longbridge.com/en/news/285339565.md)